ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "B cells"

  • 2016 American Transplant Congress

    The Effect of Rituximab on Hepatitis B Reactivation in Kidney Transplant Recipients with Resolved Hepatitis B.

    J. Lee,1 J. Park,2 J. Lee,1 S. Song,1 J. Lee,1 S.-K. Kwon,1 K. Huh,1 B. Kim,3 M. Kim,1 S. Kim,1 S. Ahn,2 Y. Kim.1

    1Surgery, Yonsei University College of Medicine, Seoul, Korea; 2Internal Medicine (Gastroenterology), Yonsei University College of Medicine, Seoul, Korea; 3Internal Medicine (Nephrology), Yonsei University College of Medicine, Seoul, Korea.

    Background: Hepatitis B virus (HBV) reactivation is a well-known complication of immunosuppressive therapy in resolved HBV (hepatitis B surface antigen [HBsAg] negative and hepatitis B…
  • 2016 American Transplant Congress

    A Prospective Carfilzomib-Based Desensitization Trial: Phase 1 Results.

    S. Tremblay,1 A. Shields,1 R. Alloway,1 P. Brailey,1 B. Abu Jawdeh,1 T. Latif,1 J. Driscoll,1 M. Pando,2 A. Girnita,1 E. Woodle.1

    1U Of Cincinnati, Cincinnati; 2Mayo Clinic, Phoenix.

    Carfilzomib (CFZ) is mechanistically distinct from bortezomib as it is an irreversible PI. Results from phase 1 of a CFZ desensitization (DS) trial are presentedMethods:…
  • 2016 American Transplant Congress

    Intravenous Immunoglobulins Failed to Prevent Acute Antibody-Mediated Rejection in Kidney Transplant Recipients with De Novo DSA within the First Year After Transplant.

    M. Matignon,1 C. Pilon,2 M. Commereuc,1 C. Grondin,2 T. Kofman,1 P. Lang,1 F. Canoui Poitrine,3 J. Cohen,2 P. Grimbert.1

    1Nephrology-Transplantation, APHP, Henri Mondor, Créteil, France; 2INSERM U955, Créteil, France; 3Public health, APHP, Henri Mondor, Créteil, France.

    BackgroundAround 25% of kidney transplant recipients develop de novo anti-HLA donor specific antibodies (DSA). Most of them are detected within the first year after transplant.…
  • 2016 American Transplant Congress

    RNAseq Transcriptome Analysis of Bone Marrow CD138+ Plasma Cell Responses to Carfilzomib Monotherapy Desensitization.

    J. Driscoll, B. Aronow, S. Tremblay, R. Alloway, E. Woodle.

    Medicine, Surgery, Biomedical Informatics, U of Cincinnati, Cincinnati Children's, Cincinnati, OH.

    Purpose: Prior studies indicate that bone marrow resident plasma cells (BMRPCs) demonstrate varying sensitivity to proteasome inhibition (PI). Effects of carfilzomib (CFZ) monotherapy desensitization on…
  • 2016 American Transplant Congress

    Post-Transplant Reduction of Long Lived Plasma Cells from Peripheral Circulation Is Associated with Acute Rejection in Kidney Transplant Recipients.

    R. Minz,1 R. Dhital,2 M. Minz,2 R. Nada,3 A. Sharma,2 S. Singh,2 D. Kenwar.2

    1Immunopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India; 2Renal Transplant Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India; 3Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

    Introduction:Plasma cells (PC) are usually defined functionally as antibody secreting cells (ASC). Depending upon their life span, they could either be short lived or long…
  • 2016 American Transplant Congress

    NK Cells Are Required in B-Cell Dependent, Antibody Mediated Islet Transplant Tolerance.

    C. Schuetz, K. Lee, L. Kojima, L. Washburn, L. Liu, W.-H. Liu, J. Kim, J. Markmann.

    Dept of Surgery, Transplant Surgery Division, Massachusetts General Hospital, Boston, MA.

    Immunologic tolerance to islets has been achieved in various rodent models using antibodies directed at CD45RB and Tim-1. We have shown that this tolerance mechanism…
  • 2016 American Transplant Congress

    Transitional B Cell T1/T2 Ratio Is a Prognostic Marker for Human Renal Allograft Deterioration.

    A. Cherukuri,1 D. Rothstein,1 R. Baker.2

    1UPMC, Pittsburgh; 2University of Leeds, Leeds, United Kingdom.

    Human transitional B cells (TrB) may play a significant role in auto and alloimmune disease. TrB express a high IL10:TNFα ratio and this fell with…
  • 2016 American Transplant Congress

    TGFb in Regulatory B Cells-Dependent Tolerance.

    H. Deirawan, L. Kojima, L. Washburn, J. Markmann, J. Kim.

    Surgery, Massachusetts General Hospital, Boston, MA.

    In transplantation, increasing evidence support that B cells can play a major regulatory role in addition to their critical functions in allo-immunity and graft rejection.…
  • 2016 American Transplant Congress

    MHC/HLA-Specific IgE in Allotransplantation.

    A. Farkas,1 U. Baranyi,1 L. Unger,1 B. Mahr,1 K. Hock,1 N. Pilat,1 H. Regele,2 M. Wahrmann,3 G. Böhmig,3 R. Valenta,4 T. Wekerle.1

    1Dept. of Surgery, Medical University of Vienna, Vienna, Austria; 2Clin. Inst. of Pathology, Medical University of Vienna, Vienna, Austria; 3Dept. of Internal Medicine III, Medical University of Vienna, Vienna, Austria; 4Dept. of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.

    Background: Donor-specific antibodies (DSA) are recognized as important factors in determining outcome in renal transplantation.Typically DSAs of the IgG isotype are measured, but little is…
  • 2016 American Transplant Congress

    Designing and Synthesizing a Novel Highly Selective Immunoproteasome Inhibitor That Promotes Long Term Heart Allograft Acceptance While Reducing Plasma Cells and Donor Specific Antibodies.

    A. Mihali,1 E. Sula Karreci,1 A. Kurdi,3 L. Riella,1 Y. Kawano,3 H. Fan,2 P. Singh,2 I. Ghobrial,3 C. Nathan,2 G. Lin,2 J. Azzi.1

    1Transplantation Research Center, Harvard Medical School, Boston; 2Department of Microbiology and Immunology, Weill Cornell Medicine, NY; 3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston.

    Antibody mediated rejection (AMR) is one of the most important barriers to improving long-term transplant outcomes. Traditional therapies for AMR do not deplete the source…
  • « Previous Page
  • 1
  • …
  • 27
  • 28
  • 29
  • 30
  • 31
  • …
  • 35
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences